The Seasonal Affective Disorder Market is expected to grow at the CAGR of 4.2% during the forecast period and is estimated to reach USD 694.9 million by 2023. Seasonal Affective Disorder (SAD) is a type of depression that occurs during a certain time of the year. This disorder is related to changes in seasons, mostly occurs in winter but some people may have this disorder in summers as well. Seasonal affective disorder is most common in women, people between the ages of 15 to 55, and the people who live far from the equator where winter daylight hours are too short. Some major symptoms of this disorder are hopelessness, increased appetite, weight gain, loss of the ability to concentrate, social withdrawal etc. There are some risk factors associated with this disorder such as major depressive disorder, Bipolar I disorder, Bipolar II disorder, and others.
Increasing prevalence and growing awareness of this disorder are driving the seasonal affective disorder market growth. Increasing number of physician visits related to seasonal affective disorder is increasing which is another growth factor for the market. Some other factors such as changing lifestyle and lack of exercise are also key drivers for the market growth. Availability and adoption of new treatments for this disorder are another important factor for the market growth. The seasonal affective disorder market is growing moderately and is expected to continue its growth during the forecast period.
Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/4123
Segments
The seasonal affective disorder market is segmented on the basis of type, which includes fall and winter SAD, spring and summer SAD, and others.
On the basis of diagnosis, the seasonal affective disorder market is segmented into physical exam, lab tests, psychological evaluation, and others. Lab tests is sub-segmented into complete blood count (CBC), thyroid blood tests, and others. Psychological evaluation includes intelligence tests, personality tests, attitude tests, achievement tests, aptitude tests, neuropsychological tests, vocational tests, direct observation tests, and others.
On the basis of treatments, the seasonal affective disorder market is segmented into light therapy (phototherapy), medications, psychotherapy, counselling, and others. Medications includes antidepressants, and others. Antidepressants is further sub-segmented into reuptake inhibitors (SSRIs), and others. Psychotherapy includes art therapy, attachment-based psychotherapy, behavioral therapy, body psychotherapy, Cognitive analytical therapy (CAT), existential psychotherapy, gestalt therapy, and others.
On the basis of end user, it is segmented into hospitals & clinics, academic institutes, medical research centers, and others.
Key Players in the Global Seasonal Affective Disorder Market
Some of the key players in this market: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein, Inc. (US), Pfizer Inc. (US), and others
Regional Analysis of the Global Seasonal Affective Disorder Market
The Americas hold the largest share in the global Seasonal affective disorder market. North America dominates the market in this region. Approximately 5% of the US population is suffering from seasonal depression Some other factors such as changing lifestyle plays an important role in market growth. South America market is also growing significantly, especially growth is higher in countries such as Brazil due to increasing awareness about various mental disorders.
The number of patients affected by seasonal affective disorder is increasing in Europe. The prevalence rate is higher in UK and Ireland. Approximately 2% population of Northern Europe is suffering from severe depression which results into seasonal affective disorder. Other European countries such as Germany and France are holding major market share in this region.
The prevalence of seasonal affective disorder in Asia Pacific region is about 0.9% which is lower as compare to North America and Europe. However, people are getting more aware about this disorder which is driving the seasonal affective disorder market growth. Some other factors such as developing health facilities, availability of treatments and products, changing lifestyle etc. are playing an important role in the growth of this market.
Due to low prevalence rate, less awareness of this disorder, and limited access to the healthcare facilities, Middle East & Africa seasonal affective disorder market is growing slower than the global average. The Middle Eastern countries are dominating this market due to developed healthcare infrastructure and increasing expenditure on health.
Sources: The National Institute of Mental Health (NIMH), National Center for Biotechnology Information, U.S. National Library of Medicine, American Psychological Association, Directorate of Industries, annual report, white paper, company presentation
Access Report https://www.marketresearchfuture.com/reports/seasonal-affective-disorder-market-4123
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Contact:
Market Research Future®
99 Hudson Street,5Th Floor
New York, New York 10013
United States of America
Seasonal Affective Disorder Market information: by type (fall and winter SAD, and others), by diagnosis (physical exam, lab tests, and others), by treatment (light therapy, medications, and others), by end user- global forecast till 2027Market Analysis The global seasonal affective disorder market is predicted to touch USD 694.9 million at a 4.2% CAGR by 2023, as per the latest Market Research Future (MRFR) report.
Based on type, the seasonal affective disorder market is segmented into spring and summer SAD, fall and winter SAD, and others.
The psychological evaluation segment is again segmented into direct observation tests, vocational tests, neuropsychological tests, aptitude tests, achievement tests, attitude tests, personality tests, and intelligence tests.
Regional Analysis By region, the seasonal affective disorder market report covers the latest trends and growth opportunities across the Americas, Europe, the Asia Pacific (APAC), and the Middle East and Africa (MEA).
This is owing to growing awareness, changing lifestyle, availability of products and treatments, and developing health facilities.
This is owing to limited access to healthcare facilities, less awareness about seasonal affective disorder, and low prevalence rate.
Market HighlightsThe global seasonal affective disorder market is growing moderately, and it is expected to grow at the same pace over the forecast period 2017-2018.
Adoption of advanced diagnosis and treatment also plays an important role in the growth of this market.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/4123The global market of seasonal affective disorder was around USD 521.0 million in 2016 and is expected to reach USD 694.9 million by 2023 at a projected CAGR of 4.2%.Major Players in Seasonal Affective Disorder MarketSome of the key market players: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Henry Schein, Inc (US), Pfizer Inc. (US)Regional AnalysisThe global seasonal affective disorder market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.The Americas dominate this market, particularly North America due to increasing prevalence of this disorder in the region.
It is estimated that around 10 million Americans are affected by this disorder.
Growing awareness in South American population regarding this disorder is major driving force.Increasing cases of seasonal affective disorder in Europe is leading the market growth.
However, increasing healthcare expenditure, growing awareness, and increasing government support to improve life of patients drive this market.The Middle East & Africa region is expected to have the least growth during the forecast period due to lack of awareness about this disorder and limited access to healthcare facilities.SegmentationThe global seasonal affective disorder market is segmented on the basis of type, which includes fall and winter SAD, spring and summer SAD, and others.On the basis of diagnosis, the market is segmented into physical exam, lab tests, psychological evaluation, and others.
Lab tests is sub-segmented into complete blood count (CBC), thyroid blood tests, and others.
Seasonal depression doesn't usually work this way, but with the news that Audi is removing one of its few convertibles from the lineup, there's nothing wrong with getting a little weepy in the middle of summer.
Audi will discontinue its A3 Cabriolet after the 2019 model year, Car and Driver reports.
It's not bringing the executioner's ax down on every A3 variant, just the drop-top, so A3 sedan fans don't have anything to worry about for the 2020 model year.
Thankfully, you can still scoop up one of the 2019 models while they're at dealers.
Each of the A3 Cabriolet's three trims can be had with one of two powertrains.
The base 2.0-liter I4 puts out 184 horsepower and 222 pound-feet of torque, and it comes mated to a seven-speed dual-clutch automatic transmission and front-wheel drive.
Due to various disorders and conditions such as seasonal affective disorder (SAD), blue light therapy has witnessed a significant demand globally. This has compelled various manufacturers to cater to such growing demands. The global light therapy market is expected to register at 4.8% over the forecast period, 2026.
Report For Sample with Table of Contents@ https://www.researchreportinsights.com/report/sample/110114802/Light-Therapy-Market
Market Dynamics: Attributed to various advantages such as increased blood circulation and cellular regeneration, acne treatment using LED light is gaining traction. Moreover, treatment through LED light treatment offers the benefits of red and blue light therapy over conventional light therapy. Such factors are driving growth of the light therapy market globally over the following decade.
Global Light Therapy Market to Grow at 4.8% CAGR throughout 2026
Segmentation Analysis: The light box segment among various among other products accounts for relatively high market share and will grow at 4.3% CAGR in the span of next ten years. Whereas, the homecare settings segment among various end users accounts for relatively high market share and will grow at a relatively high CAGR of 5.1% over the following decade. The white light among various types of light will witness a healthy growth in the span of next ten years.
Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114802/Light-Therapy-Market
Regional Analysis
Following Western Europe North America accounted for major market share of 42.5% in 2015 among various regions. Whereas, the APEJ market will expand at a relatively high CAGR of 6.5% over the following decade.
In 2014, the light therapy market in Latin America registered a 6.4% Y-o-Y growth rate. Whereas, the light therapy market in Eastern Europe will grow at 4.5% CAGR in the span of next ten years.
However, in 2014, the light therapy treatment market in Russia represented major market share in Eastern Europe. Russia will retain dominance in the region in the span of next ten years, growing at a 4.6% CAGR over the following decade.
Vendor Insights
Market players operating in the global light therapy market include Verilux, Inc., Koninklijke Philips N.V., Zepter International, Northern Light Technology, Beurer, Photomedex Inc, Lucimed SA, Nature Bright, Lumie, Chal-Tech-GmbH, Sphere Gadget Technologies and Aura Daylight.
Research Report Insights (RRI) is a leading market intelligence and consulting firm. We deliver a host of services including custom research reports, syndicated research reports, and consulting services which are personalised in nature. RRI delivers a complete packaged solution to clients; this combines current market intelligence, technology inputs, statistical anecdotes, valuable growth insights, 360-degree view of the competitive framework, and anticipated market trends.
Our research services cover global as well as regional emerging markets such as BRICS, GCC, and ASEAN. Our offerings cover a broad spectrum of verticals which include Oil and Gas, Chemicals, Materials, Energy, Technology, Automotive, and Retail. The operating model of RRI blends cross-disciplinary research experience to deploy insightful, in-depth, and actionable research.
Contact Us:
Research Report Insights
42 joseph street,
Portcarling P0B 1J0,
Muskoka, Ontario, Canada
T: +1-631-721-4201
Email: [email protected]
Web Site: http://www.researchreportinsights.com
Phone - (+91) 7875758555
Report Analysis@ https://www.researchreportinsights.com/report/rd/110114802/Light-Therapy-Market
